Connection

Co-Authors

This is a "connection" page, showing publications co-authored by MIEN-CHIE HUNG and HIROHITO YAMAGUCHI.
Connection Strength

9.994
  1. Prospects of the potential strategies to improve the efficacy of anti-PD-1/PD-L1 therapy. Clin Transl Med. 2022 05; 12(5):e803.
    View in: PubMed
    Score: 0.872
  2. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. 2022 05; 19(5):287-305.
    View in: PubMed
    Score: 0.859
  3. Regulation and Role of EZH2 in Cancer. Cancer Res Treat. 2014 Jul; 46(3):209-22.
    View in: PubMed
    Score: 0.508
  4. Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on cisplatin in non-small cell lung cancer cells. Clin Cancer Res. 2013 Feb 15; 19(4):845-54.
    View in: PubMed
    Score: 0.459
  5. Regulation of ubiquitination-mediated protein degradation by survival kinases in cancer. Front Oncol. 2012; 2:15.
    View in: PubMed
    Score: 0.430
  6. Interferon-inducible protein IFIXalpha inhibits cell invasion by upregulating the metastasis suppressor maspin. Mol Carcinog. 2008 Oct; 47(10):739-43.
    View in: PubMed
    Score: 0.340
  7. Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors. J Biomed Sci. 2022 Oct 25; 29(1):86.
    View in: PubMed
    Score: 0.226
  8. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer. 2022 10; 3(10):1211-1227.
    View in: PubMed
    Score: 0.225
  9. Structural insights into EphA4 unconventional activation from prediction of the EphA4 and its complex with ribonuclease 1. Am J Cancer Res. 2022; 12(10):4865-4878.
    View in: PubMed
    Score: 0.225
  10. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates. Am J Cancer Res. 2022; 12(4):1671-1685.
    View in: PubMed
    Score: 0.217
  11. Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Nat Commun. 2021 05 13; 12(1):2788.
    View in: PubMed
    Score: 0.204
  12. TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. J Clin Invest. 2021 04 15; 131(8).
    View in: PubMed
    Score: 0.203
  13. Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. Am J Cancer Res. 2020; 10(2):648-661.
    View in: PubMed
    Score: 0.187
  14. Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun. 2020 Jan 29; 11(1):673.
    View in: PubMed
    Score: 0.187
  15. The potential role of YAP in Axl-mediated resistance to EGFR tyrosine kinase inhibitors. Am J Cancer Res. 2019; 9(12):2719-2729.
    View in: PubMed
    Score: 0.184
  16. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun. 2019 11 08; 10(1):5114.
    View in: PubMed
    Score: 0.184
  17. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology. 2019 05; 156(6):1849-1861.e13.
    View in: PubMed
    Score: 0.174
  18. An essential role of PRMT1-mediated EGFR methylation in EGFR activation by ribonuclease 5. Am J Cancer Res. 2019; 9(1):180-185.
    View in: PubMed
    Score: 0.173
  19. EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma. Cancer Res. 2019 02 15; 79(4):819-829.
    View in: PubMed
    Score: 0.173
  20. Targeting PKCd as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. Cancer Cell. 2018 12 10; 34(6):954-969.e4.
    View in: PubMed
    Score: 0.172
  21. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell. 2018 02 12; 33(2):187-201.e10.
    View in: PubMed
    Score: 0.163
  22. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells. Breast Cancer. 2018 Jan; 25(1):74-80.
    View in: PubMed
    Score: 0.156
  23. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017 Jul 15; 23(14):3711-3720.
    View in: PubMed
    Score: 0.152
  24. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 2016 Dec 12; 30(6):925-939.
    View in: PubMed
    Score: 0.149
  25. Corrigendum: Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016 10 06; 22(10):1192.
    View in: PubMed
    Score: 0.148
  26. GSK3? inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget. 2016 Aug 30; 7(35):57131-57144.
    View in: PubMed
    Score: 0.147
  27. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016 08 30; 7:12632.
    View in: PubMed
    Score: 0.147
  28. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res. 2016; 6(8):1609-23.
    View in: PubMed
    Score: 0.146
  29. Extracellular PKM2 induces cancer proliferation by activating the EGFR signaling pathway. Am J Cancer Res. 2016; 6(3):628-38.
    View in: PubMed
    Score: 0.142
  30. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016 Feb; 22(2):194-201.
    View in: PubMed
    Score: 0.141
  31. AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. Cancer Res. 2016 Mar 15; 76(6):1451-62.
    View in: PubMed
    Score: 0.141
  32. PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. J Clin Invest. 2015 Dec; 125(12):4529-43.
    View in: PubMed
    Score: 0.139
  33. Carglumic acid promotes apoptosis and suppresses cancer cell proliferation in vitro and in vivo. Am J Cancer Res. 2015; 5(12):3560-9.
    View in: PubMed
    Score: 0.139
  34. Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. Am J Transl Res. 2015; 7(6):1009-20.
    View in: PubMed
    Score: 0.135
  35. Activation of Keap1/Nrf2 signaling pathway by nuclear epidermal growth factor receptor in cancer cells. Am J Transl Res. 2014; 6(6):649-63.
    View in: PubMed
    Score: 0.130
  36. mMAPS: a flow-proteometric technique to analyze protein-protein interactions in individual signaling complexes. Sci Signal. 2014 Mar 04; 7(315):rs1.
    View in: PubMed
    Score: 0.124
  37. Targeting the IKK?/mTOR/VEGF signaling pathway as a potential therapeutic strategy for obesity-related breast cancer. Mol Cancer Ther. 2012 Oct; 11(10):2212-21.
    View in: PubMed
    Score: 0.111
  38. Membrane-bound trafficking regulates nuclear transport of integral epidermal growth factor receptor (EGFR) and ErbB-2. J Biol Chem. 2012 May 11; 287(20):16869-79.
    View in: PubMed
    Score: 0.108
  39. Epithelial-mesenchymal transition induced by TNF-a requires NF-?B-mediated transcriptional upregulation of Twist1. Cancer Res. 2012 Mar 01; 72(5):1290-300.
    View in: PubMed
    Score: 0.107
  40. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell. 2011 Sep 13; 20(3):341-56.
    View in: PubMed
    Score: 0.104
  41. FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization. Cancer Res. 2011 Nov 01; 71(21):6878-87.
    View in: PubMed
    Score: 0.104
  42. Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase. Mol Cancer Ther. 2011 Aug; 10(8):1327-36.
    View in: PubMed
    Score: 0.102
  43. The translocon Sec61beta localized in the inner nuclear membrane transports membrane-embedded EGF receptor to the nucleus. J Biol Chem. 2010 Dec 03; 285(49):38720-9.
    View in: PubMed
    Score: 0.098
  44. Rapid detection of two-protein interaction with a single fluorophore by using a microfluidic device. Analyst. 2010 Nov; 135(11):2907-12.
    View in: PubMed
    Score: 0.098
  45. COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transport. Biochem Biophys Res Commun. 2010 Sep 03; 399(4):498-504.
    View in: PubMed
    Score: 0.097
  46. High speed digital protein interaction analysis using microfluidic single molecule detection system. Lab Chip. 2010 Jul 21; 10(14):1793-8.
    View in: PubMed
    Score: 0.095
  47. The suppression of MAD1 by AKT-mediated phosphorylation activates MAD1 target genes transcription. Mol Carcinog. 2009 Nov; 48(11):1048-58.
    View in: PubMed
    Score: 0.092
  48. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther. 2009 Aug; 8(8):2375-82.
    View in: PubMed
    Score: 0.090
  49. p53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem. 2009 Apr 24; 284(17):11171-83.
    View in: PubMed
    Score: 0.088
  50. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008 Feb; 10(2):138-48.
    View in: PubMed
    Score: 0.081
  51. Pneumatically Actuated Soft Micromold Device for Fabricating Collagen and Matrigel Microparticles. Soft Robot. 2017 Dec; 4(4):390-399.
    View in: PubMed
    Score: 0.039
  52. Microfluidic three-dimensional hydrodynamic flow focusing for the rapid protein concentration analysis. Biomicrofluidics. 2012 Jun; 6(2):24132.
    View in: PubMed
    Score: 0.028
  53. MEASUREMENT of Protein 53 Diffusion Coefficient in Live HeLa Cells Using Raster Image Correlation Spectroscopy (RICS). J Biomater Nanobiotechnol. 2010 Oct; 1(1):31-36.
    View in: PubMed
    Score: 0.024
  54. EPOX inhibits angiogenesis by degradation of Mcl-1 through ERK inactivation. Clin Cancer Res. 2009 Aug 01; 15(15):4904-14.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.